Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the Recursion OS, a platform built across diverse ...

Journal Editorial Report: The week's best and worst from Kim Strassel, Allysia Finley and Kyle Peterson. Photo: U.S. FDA via AP/Brian Snyder/Reuters/Tom Williams/CQ Roll Call via Zuma Press My ...

The clinical-stage biotech might have a successful drug on its hands, if a relatively early-stage clinical trial is any indication. Its REC-4881 did very well in the testing. 10 stocks we like better ...

A Matlab implementation of Loopy Belief Propagation for stereo matching. It uses the "Min-Sum" variation of the algorithm and the "Synchronous" message update schedule.

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

Over the past few days, XRP price prediction models have been tested as XRP experienced a wild ride, falling from above $2.80 to as low as $1.64 before rising back toward the mid-$2 level. Leveraged ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

In a recent social media post, Peter Ray, senior director of medicinal chemistry at Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), drew attention to a new article in WIRED from Veronique Greenwood ...